![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 2 of 2. This is the beginning of the thread.
Posted by JohnX2 on November 18, 2001, at 22:42:38
dxm = dextromethorphan.Just out of curiosity I tried wellbutrin
again. 1st time before taking dxm and it immediately
gave me a whopper of a tension headache. 2nd and 3rd time
with dxm, and no headache. plus, I got the
anti-depressant response a few hours ago after feeling
utter dispair earlier today. So now mr. dysthymia
is on vacation for a while, we'll see when he
returns because he always does.I'm wondering how the various metabolites of WB
are reacting. It can cause kindling from what I
understand and seizures for some, but the main
active metabolites hydroxy-bupropion and something
else have etremely long 1/2 lives (like 20+ hrs).The dxm can only be in my body at most a few hrs
and I'm wondering if this is enough for it to
counteract the parent bupropion kindling itself.
We'll see if the headache returns. I'll keep taking
a dxm dose with wellbutrin while this lasts just for kicks.
If it continues to work, then it is a good indicator
that memantine will help me.I did find a reference to nmda antagonists antagonizing
crf release and kindling in the amygdala.
I wonder how their research NMDA antagonist
2-amino-5-phosphonovaleric acid, compares to dxm or
memantine or mk-801.N-methyl-D-aspartate (NMDA)-mediated corticotropin-releasing factor (CRF) release in cultured rat amygdala neurons.
Peptides 1999;20(1):93-100 (ISSN: 0196-9781)Cratty MS; Birkle DL [Find other articles with these Authors]
Department of Pharmacology and Toxicology, West Virginia University, Robert C. Byrd Health Sciences Center, Morgantown 26506, USA.Corticotropin-releasing factor (CRF) plays an important role in the activation of centrally mediated responses to stress. The amygdala, a limbic structure involved in the stress response, has a
significant number of CRF cell bodies and CRF receptors. Activation of glutamatergic projections to the amygdala has been implicated in the stress response. Few studies have evaluated
neurotransmitter-stimulated CRF release in the amygdala. We measured the effects of glutamate (0.1-1000 microM) and N-methyl-D-aspartate (NMDA, 0.1-1000 microM) on CRF release
from the amygdala using primary neuronal cultures from embryonic rat brains (E18-19). Experiments were performed after the cultures grew for 17-20 days. CRF was measured using
radioimmunoassay. The excitatory amino acid neurotransmitters, glutamate and NMDA, stimulated CRF release in a concentration-dependent manner. The apparent EC50 values for
glutamate and NMDA were 17.5 microM and 12 microM, respectively. Consistent with a NMDA receptor-driven event, glutamate-stimulated CRF release was blocked by the NMDA
antagonist, 2-amino-5-phosphonovaleric acid (AP-5, 1-100 microM) and antagonized by the addition of 1.2 mM MgCl2 to the incubation medium. These results implicate an inhibition of
CRF release in the amygdala as a possible mechanism for the reported anxiolytic effects of NMDA antagonists.
Posted by JohnX2 on November 19, 2001, at 13:13:50
In reply to Wellbutrin + dxm part 2, posted by JohnX2 on November 18, 2001, at 22:42:38
Another dose this morning of WB 100 mg.
1st I take 60 mg dxm and then wait a short
while before taking the WB. No headache today
either. I am starting to get slurred speech
and diplopia (double vision). The slurred speech
was a side effect on Lamictal that waned,
it worries me a little. The
diplopia on Wellbutrin usually precedes a lift
of depression. Last nights hypomania petered out
but I didn't go into that weird state of total
emotional numbing and facial pain, which is
a 1st for me for a wellbutrin response.-john
>
> dxm = dextromethorphan.
>
> Just out of curiosity I tried wellbutrin
> again. 1st time before taking dxm and it immediately
> gave me a whopper of a tension headache. 2nd and 3rd time
> with dxm, and no headache. plus, I got the
> anti-depressant response a few hours ago after feeling
> utter dispair earlier today. So now mr. dysthymia
> is on vacation for a while, we'll see when he
> returns because he always does.
>
> I'm wondering how the various metabolites of WB
> are reacting. It can cause kindling from what I
> understand and seizures for some, but the main
> active metabolites hydroxy-bupropion and something
> else have etremely long 1/2 lives (like 20+ hrs).
>
> The dxm can only be in my body at most a few hrs
> and I'm wondering if this is enough for it to
> counteract the parent bupropion kindling itself.
> We'll see if the headache returns. I'll keep taking
> a dxm dose with wellbutrin while this lasts just for kicks.
> If it continues to work, then it is a good indicator
> that memantine will help me.
>
> I did find a reference to nmda antagonists antagonizing
> crf release and kindling in the amygdala.
> I wonder how their research NMDA antagonist
> 2-amino-5-phosphonovaleric acid, compares to dxm or
> memantine or mk-801.
>
> N-methyl-D-aspartate (NMDA)-mediated corticotropin-releasing factor (CRF) release in cultured rat amygdala neurons.
>
>
> Peptides 1999;20(1):93-100 (ISSN: 0196-9781)
>
> Cratty MS; Birkle DL [Find other articles with these Authors]
> Department of Pharmacology and Toxicology, West Virginia University, Robert C. Byrd Health Sciences Center, Morgantown 26506, USA.
>
> Corticotropin-releasing factor (CRF) plays an important role in the activation of centrally mediated responses to stress. The amygdala, a limbic structure involved in the stress response, has a
> significant number of CRF cell bodies and CRF receptors. Activation of glutamatergic projections to the amygdala has been implicated in the stress response. Few studies have evaluated
> neurotransmitter-stimulated CRF release in the amygdala. We measured the effects of glutamate (0.1-1000 microM) and N-methyl-D-aspartate (NMDA, 0.1-1000 microM) on CRF release
> from the amygdala using primary neuronal cultures from embryonic rat brains (E18-19). Experiments were performed after the cultures grew for 17-20 days. CRF was measured using
> radioimmunoassay. The excitatory amino acid neurotransmitters, glutamate and NMDA, stimulated CRF release in a concentration-dependent manner. The apparent EC50 values for
> glutamate and NMDA were 17.5 microM and 12 microM, respectively. Consistent with a NMDA receptor-driven event, glutamate-stimulated CRF release was blocked by the NMDA
> antagonist, 2-amino-5-phosphonovaleric acid (AP-5, 1-100 microM) and antagonized by the addition of 1.2 mM MgCl2 to the incubation medium. These results implicate an inhibition of
> CRF release in the amygdala as a possible mechanism for the reported anxiolytic effects of NMDA antagonists.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.